Loading data for ATRC — first visit, this takes a few seconds.

Alert

AtriCure Inc. (ATRC)

NasdaqGM: ATRC · Real-Time Price · USD

48.98

+1.49 (3.14%)

At close: Aug 24, 2026, 8:00 PM

49.28

+0.00%

After-hours: 4:10 PM

The price, the headline numbers and the latest news, in one place.

3.14% (1D)

No data available

Bid	27.83
Market Cap	2.51B
Revenue (ttm)	569.62M
Net Income (ttm)	10.55M
	1.23
	0.21
	234.67
	114.14
P/B (ttm)	4.85
P/S (ttm)	4.40
Earnings Date	May 5, 2026

Ask	49.7
Volume	389,737
Avg. Volume (20D)	910,514
Open	47.48
Previous Close	47.49
Day's Range	46.99 - 49.20
52-Week Range	25.36 - 49.20
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ATRC

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a ...

[Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

IPO Date Aug 5, 2005

Employees 1,350

Stock Exchange NasdaqGM

Ticker Symbol ATRC

Website https://www.atricure.com

Full Company Profile

Financial Performance

In 2025, AtriCure's revenue was 534.53M, an increase of 14.88% compared to the previous year's 465.31M. Earnings were -11.45M, a decrease of -74.39%.

Financial Statements

Earnings Surprise

AtriCure has released their quarterly earnings on Jul 23, 2026:

Revenue of $153.6M misses estimates by $0, with 12.83% YoY growth.
EPS of 0.18 exceeds estimates by 0.16, with 228.57% YoY growth.

Next Earnings Release

AtriCure Inc. is scheduled to release its earnings on May 5, 2026, after market closes.
Analysts project revenue of ... Upgrade

News

2 weeks ago · MarketBeat

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoptio...

2 weeks ago · Motley Fool

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.

2 weeks ago · Motley Fool

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.

3 weeks ago · Simply Wall St.

Project Horizon and Outlook Upgrade Might Change The Case For Investing In Inspire Medical Systems (INSP)

Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly re...

3 weeks ago · Zacks

Are Options Traders Betting on a Big Move in AtriCure Stock?

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

Page 1 of 2

AtriCure Inc. (ATRC)